3646 results for «467»
3646 results
Road to relief - Effective treatment of refractory angina patients with Shockwave Reducer
22 May 2025 – From EuroPCR 2025
Refractory angina affects more than 100 million people globally and is associated with a significantly increased risk of adverse cardiovascular events. Treating this condition effectively remains a major clinical challenge. This session provides detailed insights into the use of the Shockwave Reducer device as an innovative therapeutic...
Techniques for the treatment of left main lesions
20 May 2025 – From EuroPCR 2025
Discover contemporary techniques for treating left main coronary artery lesions with a focus on ultra low-contrast PCI, management of calcified Medina 0-0-1 lesions, and troubleshooting intravascular lithotripsy. This session provides practical insights into complex lesion treatment to enhance safety and efficacy.
Shaping the future of cardiology - A journey of meaningful innovation in structural heart and coronary
22 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session highlights the latest device innovations reshaping interventional cardiology. Learn how the Myval OCTAPRO THV combines predictable deployment with minimal foreshortening for improved outcomes in structural heart procedures. In the coronary space, the session explores the renewed appeal of the “leave nothing behind”...
Invasive treatment of refractory angina
20 May 2025 – From EuroPCR 2025
Explore invasive treatment options for refractory angina through clinical case presentations emphasizing coronary physiology guidance, coronary microvascular disease management, and innovative therapies such as coronary sinus reducer implantation. This session highlights provocative test-guided approaches to optimize patient outcomes.
Simplify PCI! Know where and how to win with drug-coated balloon
22 May 2025 – From EuroPCR 2025
This session provides a comprehensive update on the use of drug-coated balloons (DCBs) to simplify percutaneous coronary intervention (PCI). It reviews various types of drugs, coatings, and balloon technologies used in DCBs, alongside the latest clinical data supporting their safety and efficacy. It also offers practical insights into...
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)